Key facts
- Reprieve Cardiovascular’s last known valuation is $100.0M (Sep 2025).
- It has raised $103.0M across 5 recorded rounds; the latest was Early Stage VC ($30.9M) in May 2025.
- Notable investors include Deerfield Management, Arboretum Ventures, Lightstone Ventures, Abiomed, Cadence Capital — 11 tracked in total.
- Reprieve Cardiovascular has filed 6 Form Ds with the SEC since 2020, most recently Jun 2025 ($30.9M sold to 12 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 5 rounds
- ·The complete investor list — 11 names
- ·Watchlist + deal alerts for Reprieve Cardiovascular
Funding rounds
5 roundsAbout Reprieve Cardiovascular
Developer of an acute decompensated heart failure (ADHF) treatment medical device designed to help patients experience life without limits. The company's device offers a proprietary method of diuretic therapy that provides precise and predictable management of a patient's fluid levels, guarding against dangerous fluid imbalances and controls over diuretic therapy, enabling medical practitioners to ensure a quality of life for the patient.
- Sector
- Healthcare
- HQ
- Milford, MA, United States
- Founded
- 2018
- Employees
- 28
- Website
- reprievecardio.com/
- Ownership
- Privately Held (backing)
Reprieve Cardiovascular doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Reprieve Cardiovascular shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Reprieve Cardiovascular in its N-PORT filings yet. We sweep new filings monthly.